nitric oxide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Assessed by visual inspection under ordinary laboratory lighting |
| Molecular mass | Approximately 1419 Da | Monoisotopic mass for the fifteen-residue sequence |
| Solubility class | Freely soluble in water | Stock solutions commonly prepared in water or aqueous buffer |
| Typical storage temperature | -20 °C or below, desiccated | Lyophilized powder; repeated freeze-thaw cycles are usually avoided |
| Common analytical method | Reversed-phase HPLC with UV detection | Frequently paired with mass spectrometry to confirm identity |
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated sequences and other synthesis by-products. Mass spectrometry, typically electrospray ionization coupled to liquid chromatography, confirms the expected mass and helps detect modifications. Amino acid analysis can verify composition when residue-level confirmation is needed. Because common impurities differ from the target by only one or two residues, chromatographic resolution often matters more than a single headline purity percentage. Impurity profiles are most informative when compared against a validated reference standard.
Lyophilized material is generally reported as stable for extended periods when kept cold, dry, and protected from light. In solution, the main degradation routes for a peptide of this type are hydrolysis of peptide bonds and aggregation. The sequence contains no cysteine, so disulfide-driven oxidation is not a primary concern, though methionine and tryptophan are also absent. Stability depends on pH, buffer composition, and concentration, with acidic conditions often reported as more favorable than neutral or alkaline ones. Repeated freeze-thaw cycles can promote aggregation, and how fast degradation proceeds at room temperature in specific formulations remains an open question.
== Bibliography == Lui, G.; Bruenger, F.W.; Barrios, A. M.; Miller, S.C. (1995). "Synthesis of 2-Alkyl-3-Hydroxy-4-Pyridinone-Ribonucleosides, Potential Oral Iron Chelators". Nucleosides and Nucleotides. 14: 1901–1904. Barrios, A.M. and Lippard, S.J. (2000). "Interaction of Urea with a Hydroxide-Bridged Dinuclear Nickel Center: An Alternative Model for the Mechanism of Urease". J. Am. Chem. Soc.. 122(38): 9172–9177. Barrios, A.M. and Craik, C.S. (2002). "Scanning the Prime-Site Substrate Specificity of Proteolytic Enzymes: A Novel Assay Based on Ligand-Enhanced Lanthanide Ion Fluorescence". Bioorg. Med. Chem. Lett.. 12: 3619–3623. Stanford, S.M.; Panchal, R.G.; Walker, L.M.; Falk, M.D.; Mitra, S.; Damle, S.S.; Ruble, D.; Kaltcheva, T.; Zhang, S.; Zhang, Z.-Y.; Bavari, S.; Barrios, A.M.; Bottini, N. (2012). "High-Throughput Screen Using a Single-Cell Tyrosine Phosphatase Assay Reveals Biologically Active CD45 Inhibitors". Proc. Natl. Acad. Sci.. 109(35): 13972–13977. Barrios, A. and Mitra, S. (July 2, 2015). "Coumarin-based amino acids for use in enzyme activity and substrate specificity assays". United States Patent and Trademark Office. Bottini, N.; Stanford. S.; Barrios, A.; Mitra, S. (March 19, 2013). "Method for monitoring intracellular tyrosine phosphatase activity". United States Patent and Trademark Office. Debnath, A.; Parsonage, D.; Andrade, R.; He, C.; Cobo, E.; Hirata, K.; Chen, S.; Garcia-Rivera, G.; Orozco, E.; Martinez, M.; Gunatilleke, S.; Barrios, A.M.; Arkin, M.; Poole, L.; McKerrow, J.; Reed, S. (2012).
== Motivation == The dramatic increase in genome sequencing technology has caused the number of protein sequences deposited into public databases to grow apparently exponentially. To cope with the influx of sequences, databases use computational predictions to auto-annotate individual protein's functions. While these computational methods offer the advantages of being extremely high-throughput and generally provide accurate broad classifications, exclusive use has led to a significant level of misannotation of enzyme function in protein sequence databases. Thus although the information now available represents an unprecedented opportunity to understand cellular metabolism across a wide variety of organisms, which includes the ability to identify molecules and/or reactions that may benefit human quality of life, the potential has not been fully actualized. The biological community's ability to characterize newly discovered proteins has been outstripped by the rate of genome sequencing, and the task of assigning function is now considered the rate-limiting step in understanding biological systems in detail.
=== Key challenges === LEDs require optimized efficiency to hinge on ongoing improvements such as phosphor materials and quantum dots. The process of down-conversion (the method by which materials convert more-energetic photons to different, less energetic colors) also needs improvement. For example, the red phosphors that are used today are thermally sensitive and need to be improved in that aspect so that they do not color shift and experience efficiency drop-off with temperature. Red phosphors could also benefit from a narrower spectral width to emit more lumens and becoming more efficient at converting photons. In addition, work remains to be done in the realms of current efficiency droop, color shift, system reliability, light distribution, dimming, thermal management, and power supply performance. Early suspicions were that the LED droop was caused by elevated temperatures. Scientists showed that temperature was not the root cause of efficiency droop. The mechanism causing efficiency droop was identified in 2007 as Auger recombination, which was taken with mixed reaction. A 2013 study conclusively identified Auger recombination as the cause.
Sources: en.wikipedia.org
are different quantities – the former describes the number of recovered at t = 0 whereas the latter describes the ratio between the frequency of contacts to the frequency of recovery. As implied by the variable function of t, the model is dynamic in that the numbers in each compartment may fluctuate over time. The importance of this dynamic aspect is most obvious in an endemic disease with a short infectious period, such as measles in the UK prior to the introduction of a vaccine in 1968. Such diseases tend to occur in cycles of outbreaks due to the variation in number of susceptibles (S(t)) over time. During an epidemic, the number of susceptible individuals falls rapidly as more of them are infected and thus enter the infectious and removed compartments. The disease cannot break out again until the number of susceptibles has built back up, e.g. as a result of offspring being born into the susceptible compartment.
An outbreak of avian botulism leads to the deaths of about 1,000 birds at the Waikouaiti wastewater treatment plant near Dunedin and the Washdyke Lagoon near Timaru. 27 January – New Zealand Foreign Minister Winston Peters' suspends New Zealand's aid programme to Kiribati after Kiribati President Taneti Maamau cancelled three pre-arranged meetings including one scheduled for mid January 2025. The New Zealand Government had wanted to discuss how NZ$102 million worth of aid money allocated to Kiribati between 2021 and 2024 was being spent. 29 January: Prime Minister Luxon and Transport Minister Chris Bishop announces plans by the Government to reverse blanket speed limits on 38 sections of the New Zealand state highway network and seek public consultation on raising the speed limits for another 49 state highway sections. Advocacy group Toitū te Tiriti files an urgent Waitangi Tribunal claim against proposed Regulatory Standards Bill, claiming it would undermine the Treaty of Waitangi. 30 January: Mount Taranaki is officially recognised as a person under the name Taranaki Maunga. The $130 million Queenstown Town Centre arterial road opens. 31 January: Health Minister Simeon Brown confirms that a new Dunedin Hospital will be built on the site of the former Cadbury factory at a cost of NZ$1.9 billion. A power outage affects 22,000 Transpower customers in Rotorua. The Royal New Zealand Air Force formally retires its fleet of five C-130H Hercules planes.
== L == Lamina A layer of neurons in a neural structure. In the spinal cord and cerebral cortex, laminae are functionally and anatomically distinct. Lateral geniculate nucleus (LGN) A relay center in the thalamus that receives input from the retina and sends visual information to the visual cortex. Lateral inhibition A neural mechanism in which an excited neuron reduces the activity of its neighbors. Enhances contrast in sensory systems such as vision and touch. Lateral sulcus A deep groove in the cerebral cortex that separates the frontal lobe and parietal lobe from the temporal lobe. Learning The acquisition of new knowledge or skills through experience, study, or teaching. In neuroscience, learning is linked to synaptic plasticity and neural circuit changes. Learning A neurobiological process through which experience induces lasting changes in the nervous system, leading to the acquisition or modification of behavior, knowledge, or skills. Lentiform nucleus A structure within the basal ganglia composed of the putamen and globus pallidus, involved in motor control and learning. Lesion Damage or abnormal change in brain tissue, caused by injury, stroke, disease, or surgery. Lesion studies are used to investigate brain function. Levodopa A precursor to dopamine used in the treatment of Parkinson’s disease. It crosses the blood–brain barrier and is converted to dopamine in the brain. Limbic system A group of interconnected brain structures involved in emotion, motivation, memory, and olfaction. Includes the amygdala, hippocampus, and cingulate cortex.
Sources: en.wikipedia.org
Cilengitide (EMD 121974) is a molecule designed and synthesized at the Technical University of Munich in collaboration with Merck KGaA in Darmstadt. It is based on the cyclic peptide cyclo(-RGDfV-), which is selective for αv integrins, which are important in angiogenesis (forming new blood vessels), and other aspects of tumor biology. Hence, it is under investigation for the treatment of glioblastoma, where it may act by inhibiting angiogenesis, and influencing tumor invasion and proliferation. The European Medicines Agency has granted cilengitide orphan drug status. Cilengitide seems to function by inhibiting the FAK/Src/AKT pathway and inducing apoptosis in endothelial cells. Preclinical studies in mice of cilengitide were able to demonstrate efficacious tumor regression. In a rat xenograft model, cilengitide was able to potentiate the cytotoxic effects of radiation when cilengitide was administered prior to radiation therapy. When combined with radiation, inhibition of integrin expression by cilengitide synergistically improves the cytotoxic effects of ionizing radiation for glioblastoma.
immunohistochemistry (IHC) A branch of histochemistry which makes use of antibodies conjugated to some kind of molecular label in order to detect the presence or localization of complementary antigenic structures in tissue samples. See also immunostaining.
In May 2014, researchers announced that they had successfully introduced two new artificial nucleotides into bacterial DNA, alongside the four naturally occurring nucleotides, and by including individual artificial nucleotides in the culture media, were able to passage the bacteria 24 times; they did not create mRNA or proteins able to use the artificial nucleotides.
Sources: en.wikipedia.org
It is a synthetic peptide built from fifteen amino acids, with a mass of roughly 1419 daltons. The sequence is reported to match a fragment of a protein present in human gastric juice. It is not a naturally circulating hormone.
It is normally supplied as a lyophilized powder in a sealed vial. The powder dissolves readily in water, and stock solutions are typically prepared shortly before use. Cold storage is standard laboratory practice.
The letters are generally read as shorthand for body protection compound. That label comes from the original research context rather than from formal nomenclature. No standardized nonproprietary name exists for the peptide.
It is not authorized as a medicine in the United States or the European Union. Regulatory treatment varies by jurisdiction, and in several places it is handled as a research chemical. Therapeutic claims are not supported by large human trials.